Qnasl beclomethasone dipropionate nasal aerosol: Phase III data

A double-blind, U.S. Phase III trial in 529 patients aged 12 and older showed that once-daily 320 ug Qnasl met the primary endpoint of improving weekly averages of 24-hour reflective TNSS from baseline over the first 30 weeks of the 52-week treatment period vs. placebo (p<0.001). Qnasl also significantly improved both reflective and instantaneous TNSS averaged over a 24-hour period from baseline to week 52 vs. placebo (p<0.001 for both). Additionally, Qnasl led to greater improvements in individual nasal symptoms, including nasal congestion, nasal itching, rhinorrhea and sneezing, vs. placebo. Qnasl was well tolerated with nasopharyngitis, epistaxis, upper respiratory tract infections, sinusitis and headaches reported as the most common adverse events. Data were presented at the American Academy of Allergy, Asthma and Immunology meeting in Orlando. ...